Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

OPK

Opko Health Inc

May 03 • 09:59AM ET

1.34

Dollar change +0.04
Percentage change 2.69	%

Healthcare • Diagnostics & Research • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: IWM VB VTI VXF IWN IBB VBR FNDA SCHA VBK

Index	RUT	P/E	-	EPS (ttm)	-0.25	Insider Own	52.98%	Shs Outstand	773.28M	Perf Week	5.95%
Market Cap	930.48M	Forward P/E	-	EPS next Y	-0.26	Insider Trans	3.16%	Shs Float	327.73M	Perf Month	-1.84%
Income	-188.89M	PEG	-	EPS next Q	-0.10	Inst Own	27.48%	Short Float	23.81%	Perf Quarter	34.17%
Sales	863.49M	P/S	1.08	EPS this Y	-46.29%	Inst Trans	-3.05%	Short Ratio	8.96	Perf Half Y	6.80%
Book/sh	1.80	P/B	0.74	EPS next Y	29.96%	ROA	-9.04%	Short Interest	78.03M	Perf Year	-12.75%
Cash/sh	0.14	P/C	9.70	EPS next 5Y	12.00%	ROE	-12.80%	52W Range	0.85 - 2.24	Perf YTD	-11.59%
Dividend Est.	-	P/FCF	-	EPS past 5Y	1.56%	ROI	-11.29%	52W High	-40.40%	Beta	1.75
Dividend TTM	-	Quick Ratio	1.22	Sales past 5Y	3.29%	Gross Margin	26.88%	52W Low	56.76%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	1.55	EPS Y/Y TTM	44.76%	Oper. Margin	-18.31%	RSI (14)	64.81	Volatility	4.39% 4.72%
Employees	3930	Debt/Eq	0.24	Sales Y/Y TTM	-14.02%	Profit Margin	-21.87%	Recom	1.00	Target Price	4.25
Option/Short	Yes / Yes	LT Debt/Eq	0.20	EPS Q/Q	22.10%	Payout	-	Rel Volume	0.69	Prev Close	1.30
Sales Surprise	2.46%	EPS Surprise	10.00%	Sales Q/Q	-1.89%	Earnings	Feb 27 AMC	Avg Volume	8.71M	Price	1.34
SMA20	5.60%	SMA50	19.71%	SMA200	-2.66%	Trades		Volume	729,310	Change	2.69%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-29-23	Upgrade	Barrington Research	Mkt Perform → Outperform	$2
Dec-15-22	Initiated	H.C. Wainwright	Buy	$3
Jan-24-22	Downgrade	Barrington Research	Outperform → Mkt Perform
Jun-21-21	Initiated	Ladenburg Thalmann	Buy	$7
Nov-25-19	Initiated	Piper Jaffray	Overweight	$2.50
Mar-02-18	Downgrade	JP Morgan	Neutral → Underweight
Sep-14-17	Downgrade	JP Morgan	Overweight → Neutral
Jun-21-16	Reiterated	Standpoint Research	Buy	$16 → $18
Jun-03-16	Initiated	Standpoint Research	Buy	$16
Mar-31-16	Reiterated	Barrington Research	Outperform	$17 → $16
Oct-16-15	Initiated	JP Morgan	Overweight	$14
Sep-11-15	Downgrade	Jefferies	Buy → Hold
Mar-03-15	Downgrade	Oppenheimer	Outperform → Perform
May-12-14	Reiterated	Oppenheimer	Outperform	$13 → $12
Mar-14-14	Initiated	Oppenheimer	Outperform	$13
Nov-13-13	Reiterated	Ladenburg Thalmann	Buy	$10 → $14.50
May-30-13	Reiterated	Ladenburg Thalmann	Buy	$8.50 → $10
Oct-22-12	Initiated	Barrington Research	Outperform	$6
Dec-01-11	Reiterated	Ladenburg Thalmann	Buy	$6 → $8.50
Jul-14-11	Initiated	Ladenburg Thalmann	Buy	$6

Show Previous Ratings

Today 08:00AM	OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024 (GlobeNewswire)
Apr-01-24 01:01PM	OPKO Health (OPK) to Restructure After Asset Buyout by Labcorp (Zacks) +9.17%
Mar-28-24 11:08PM	Labcorp inks $237.5M buyout of Opkos reproductive, womens health testing assets (MedTech Dive) +12.15%
08:00AM	Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business (PR Newswire)
Mar-25-24 09:57AM	OPKO Health (OPK) And Entera Bio Announce Data for GLP-2 (Zacks)
08:00AM	Loading…
Mar-20-24 08:00AM	Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome (GlobeNewswire)
Mar-05-24 08:52AM	AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV (GlobeNewswire) -6.51%
Feb-29-24 08:31AM	OPKO Health, Inc. (NASDAQ:OPK) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-28-24 09:31AM	NextPlat Opens OPKO Health-Branded Storefront on Alibaba's Tmall Global Platform in China on March 1st (PR Newswire) -6.14%
09:02AM	OPKO Health's (OPK) Q4 Earnings Match Estimates, Revenues Top (Zacks)
06:18AM	Q4 2023 OPKO Health Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-27-24 09:00PM	Opko Health (OPK) Q4 2023 Earnings Call Transcript (Motley Fool) +5.37%
07:30PM	OPKO Health (OPK) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
06:10PM	OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
05:08PM	OPKO Health: Q4 Earnings Snapshot (Associated Press Finance)
04:43PM	Loading…
04:43PM	OPKO Health Inc (OPK) Reports Fourth Quarter 2023 Results (GuruFocus.com)
04:05PM	OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results (GlobeNewswire)
Feb-26-24 09:16AM	Gear Up for OPKO Health (OPK) Q4 Earnings: Wall Street Estimates for Key Metrics (Zacks) +5.34%
Feb-22-24 04:05PM	OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024 (GlobeNewswire)
Feb-08-24 01:48PM	Hedge Fund and Insider Trading News: Adam Schwartz, Bill Ackman, Eisler Capital, Brevan Howard Asset Management, Balyasny Asset Management, Citadel LLC, OPKO Health, Inc. (OPK), and More (Insider Monkey)
Feb-05-24 08:09AM	NextPlat Receives Initial Approvals to Launch OPKO Health-Branded Storefront on Alibaba's Tmall Global Platform in China (PR Newswire)
Jan-22-24 11:48AM	3 Stocks with Major Insider Buying This Month (InvestorPlace)
Jan-09-24 04:05PM	OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser's Option to Purchase Additional Notes (GlobeNewswire)
Jan-08-24 08:00AM	OPKO Health to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +12.54%
Jan-04-24 11:31PM	OPKO Health Announces Pricing of Private Offering of $200 Million Convertible Senior Notes Due 2029 (GlobeNewswire) -39.55%
Jan-03-24 05:05PM	OPKO Health Announces Private Offering of Convertible Senior Notes Due 2029 (GlobeNewswire)
Dec-07-23 10:20AM	Here's Why You Should Retain OPKO Health (OPK) Stock for Now (Zacks)
Dec-06-23 11:30AM	Why Is OPKO Health (OPK) Up 18.7% Since Last Earnings Report? (Zacks)
Nov-28-23 07:00AM	BioReference Health and Prognos Health Collaborate to Advance Precision Medicine and Testing (PR Newswire)
Nov-07-23 10:36AM	Q3 2023 OPKO Health Inc Earnings Call (Thomson Reuters StreetEvents)
10:29AM	Loading…
10:29AM	OPKO Health (OPK) Q3 Earnings Lag Estimates, Revenues Top (Zacks)
09:19AM	OPKO Health, Inc. (NASDAQ:OPK) Q3 2023 Earnings Call Transcript (Insider Monkey)
06:45AM	BioReference Signs On as the First Laboratory to Use MSK-ACCESS Powered with SOPHiA DDM (PR Newswire)
01:00AM	Opko Health (OPK) Q3 2023 Earnings Call Transcript (Motley Fool)
Nov-06-23 07:30PM	OPKO Health (OPK) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:30PM	OPKO Health: Q3 Earnings Snapshot (Associated Press Finance)
05:01PM	OPKO Health Inc (OPK) Reports Third Quarter 2023 Financial Results (GuruFocus.com)
04:05PM	OPKO Health Reports Third Quarter 2023 Business Highlights and Financial Results (GlobeNewswire)
Nov-02-23 10:00AM	New Clinical Data on OPKO Health's RAYALDEE (ER Calcifediol) Presented at Kidney Week 2023 (GlobeNewswire)
Oct-31-23 08:00AM	OPKO Health to Report Third Quarter 2023 Financial Results on November 6, 2023 (GlobeNewswire)
Oct-25-23 04:25PM	OPKO Health to Present New Clinical Data on Rayaldee (ER Calcifediol) at Kidney Week 2023 (GlobeNewswire)
Oct-12-23 10:50AM	NextPlat's Florida E-Commerce Development Program to Launch the Online Sales of OPKO Healthcare Products in China on Alibaba's Tmall Global (ACCESSWIRE)
Oct-06-23 12:03PM	OPKO Health (OPK) Gets BARDA Contract to Combat Antibody Threats (Zacks)
Sep-29-23 01:03PM	OPKO Health Inc (OPK): A Deep Dive into Its Performance Potential (GuruFocus.com) +6.67%
Sep-28-23 07:36PM	OPKO Health (OPK) - A Fairly Valued Stock with Room for Growth? (GuruFocus.com)
04:08PM	ModeX Therapeutics Secures BARDA Contract to Develop Novel Multispecific Antibodies Against Viral Infectious Disease Threats (GlobeNewswire)
Sep-13-23 01:18PM	OPKO Health (OPK) Ties Up for Oral Peptide Tablet Formulations (Zacks)
Sep-12-23 08:30AM	Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes (GlobeNewswire)
Aug-28-23 11:56AM	Reasons to Retain OPKO Health (OPK) Stock in Your Portfolio (Zacks)
Aug-07-23 01:21PM	OPKO Health (OPK) Q2 Earnings and Revenues Top Estimates (Zacks) -8.54%
Aug-04-23 01:00AM	Opko Health (OPK) Q2 2023 Earnings Call Transcript (Motley Fool) +7.57%
Aug-03-23 05:55PM	OPKO Health (OPK) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +5.11%
04:48PM	OPKO Health: Q2 Earnings Snapshot (AP Finance)
04:05PM	OPKO Health Reports Second Quarter 2023 Business Highlights and Financial Results (GlobeNewswire)
Jul-25-23 04:05PM	OPKO Health to Report Second Quarter 2023 Financial Results on August 3, 2023 (GlobeNewswire)
Jul-23-23 08:11AM	OPKO Health (NASDAQ:OPK) investors are sitting on a loss of 61% if they invested three years ago (Simply Wall St.)
Jul-12-23 08:25AM	Strength Seen in Tandem Diabetes Care, Inc. (TNDM): Can Its 8.9% Jump Turn into More Strength? (Zacks)
Jun-29-23 03:51PM	Why Shares of Opko Health Jumped on Thursday (Motley Fool) +13.66%
11:23AM	OPKO Health's (OPK) NGENLA Approved by FDA for GHD Treatment (Zacks)
09:53AM	Disney downgraded, Micron upgraded: Wall Street's top analyst calls (The Fly)
08:10AM	Pfizer (PFE) Gets FDA Nod for Growth Hormone Deficiency Drug (Zacks)
Jun-28-23 07:03AM	UPDATE 3-Pfizer-OPKO's growth hormone drug gets US approval in kids (Reuters)
06:51AM	US FDA approves Pfizer's drug for growth hormone deficiency (Reuters)
06:45AM	FDA Approves Pfizers NGENLA, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency (Business Wire)
Jun-08-23 07:11AM	Unpleasant Surprises Could Be In Store For OPKO Health, Inc.'s (NASDAQ:OPK) Shares (Simply Wall St.)
Jun-02-23 11:31AM	Why Is OPKO Health (OPK) Down 17.2% Since Last Earnings Report? (Zacks)
May-10-23 06:13AM	Gary Nabel Spends US$541k On OPKO Health Stock \ (Simply Wall St.)
May-04-23 12:23PM	OPKO Health (OPK) Q1 Earnings and Revenues Top Estimates (Zacks) +10.46%
05:48AM	Q1 2023 OPKO Health Inc Earnings Call (Thomson Reuters StreetEvents)
May-03-23 10:00PM	Opko Health (OPK) Q1 2023 Earnings Call Transcript (Motley Fool)
06:25PM	OPKO Health (OPK) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:23PM	OPKO Health: Q1 Earnings Snapshot (AP Finance)
04:05PM	OPKO Health Reports First Quarter 2023 Business Highlights and Financial Results (GlobeNewswire)
Apr-25-23 04:05PM	OPKO Health to Report First Quarter 2023 Financial Results on May 3, 2023 (GlobeNewswire) -6.16%
Apr-13-23 07:46AM	With 46% ownership, insiders at OPKO Health, Inc. (NASDAQ:OPK) are pretty optimistic and have been buying recently (Simply Wall St.) +5.44%
Mar-17-23 06:21AM	The Chairman & CEO of OPKO Health, Inc. (NASDAQ:OPK), Phillip Frost, Just Bought A Few More Shares (Simply Wall St.)
Mar-14-23 12:08PM	OPKO Health (OPK) to Develop EBV Vaccine With Latest Tie-Up (Zacks) +7.20%
Mar-09-23 03:42PM	10 Penny Stocks with Insider Buying (Insider Monkey) +7.08%
08:00AM	OPKO Health to Hold Virtual R&D Day on March 20, 2023 (GlobeNewswire)
Mar-08-23 04:34PM	Why OPKO Health Shares Jumped on Wednesday (Motley Fool) +6.60%
12:01PM	OPKO Health's Cancer & Infectious Disease Focused Subsidiary Inks Vaccine Development Pact With Merck (Benzinga)
08:05AM	Opko Health shares rise on Merck deal for experimental Epstein-Barr vaccine (Reuters)
08:01AM	Merck, Opko Health sign deal for experimental Epstein-Barr virus vaccine (Reuters)
08:00AM	OPKO Healths ModeX Therapeutics Enters into Exclusive Worldwide License and Collaboration Agreement with Merck to Develop Epstein-Barr Virus Vaccine Candidate (GlobeNewswire)
Feb-26-23 07:13AM	OPKO Health Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
06:40AM	OPKO Health, Inc. (NASDAQ:OPK) Q4 2022 Earnings Call Transcript (Insider Monkey)
Feb-24-23 10:43AM	OPKO Health (OPK) Q4 Earnings Match Estimates, Revenues Top (Zacks) -5.36%
07:11AM	Q4 2022 OPKO Health Inc Earnings Call (Thomson Reuters StreetEvents)
01:00AM	Opko Health (OPK) Q4 2022 Earnings Call Transcript (Motley Fool)
Feb-23-23 04:05PM	OPKO Health Reports Fourth Quarter 2022 Business Highlights and Financial Results (GlobeNewswire) +5.66%
Feb-16-23 12:17PM	Here's Why You Should Retain OPKO Health (OPK) Stock for Now (Zacks)
11:41AM	OPKO Health to Report Fourth Quarter 2022 Financial Results on February 23, 2023 (GlobeNewswire)
Feb-13-23 06:03AM	OPKO Health (NASDAQ:OPK investor five-year losses grow to 68% as the stock sheds US$77m this past week (Simply Wall St.)
Feb-09-23 07:05AM	BioReference Now Offers the Only FDA-Approved Dual-Stain Triage Test to Enhance Cervical Cancer Screenings (PR Newswire)
Jan-14-23 07:26AM	Is There An Opportunity With OPKO Health, Inc.'s (NASDAQ:OPK) 44% Undervaluation? (Simply Wall St.)
Jan-03-23 08:00AM	OPKO Health to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-28-22 10:06AM	3 Reasons to Retain OPKO Health (OPK) Stock in Your Portfolio (Zacks)
Nov-29-22 10:47AM	Here's Why You Should Hold OPKO Health (OPK) Stock For Now (Zacks)
Nov-16-22 05:08AM	Phillip Frost Is The Chairman & CEO of OPKO Health, Inc. (NASDAQ:OPK) And Just Spent US$319k On Shares (Simply Wall St.)
Nov-09-22 08:39AM	OPKO Health (OPK) Q3 Earnings Lag Estimates, Revenues Top (Zacks) -16.22%

OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment includes the clinical laboratory operations of BioReference, as well as point-of-care operations. The Pharmaceuticals segment includes pharmaceutical operations in Chile, Mexico, Ireland, Israel, and Spain and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FROST PHILLIP MD ET AL	CEO & Chairman	Mar 18 '24	Buy	0.87	500,000	437,100	210,968,225	Mar 18 04:45 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Mar 14 '24	Buy	0.89	500,000	444,300	210,468,225	Mar 14 05:00 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Mar 13 '24	Buy	0.93	500,000	463,750	209,968,225	Mar 13 04:44 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Mar 12 '24	Buy	0.93	600,000	559,380	209,468,225	Mar 12 05:27 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Feb 28 '24	Buy	0.99	500,000	496,150	208,868,225	Feb 28 05:31 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Feb 21 '24	Buy	0.99	1,000,000	991,700	208,368,225	Feb 21 05:10 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Feb 07 '24	Buy	0.98	1,500,000	1,462,800	207,368,225	Feb 07 05:09 PM
KRASNO RICHARD M	Director	Jan 29 '24	Buy	0.99	30,000	29,838	103,333	Jan 29 03:30 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Jan 19 '24	Buy	0.98	500,000	488,650	205,868,225	Jan 19 04:54 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Jan 18 '24	Buy	0.97	400,000	386,200	205,368,225	Jan 18 05:06 PM
HSIAO JANE PH D	Vice Chairman & CTO	Jan 17 '24	Buy	0.95	150,000	142,500	27,999,880	Jan 17 05:09 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Jan 16 '24	Buy	0.95	1,000,000	954,300	204,968,225	Jan 16 05:03 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Jan 11 '24	Buy	0.94	511,531	480,379	203,968,225	Jan 11 05:15 PM
Nabel Gary J.	Chief Innovation Officer	Jan 08 '24	Buy	0.93	216,184	200,427	351,442	Jan 10 05:56 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Jan 05 '24	Buy	0.90	1,500,000	1,344,600	203,456,694	Jan 08 08:54 AM
Zerhouni Elias A.	Vice Chairman and President	Jan 05 '24	Buy	0.93	550,300	514,093	20,327,814	Jan 05 05:26 PM
HSIAO JANE PH D	Vice Chairman & CTO	Jan 05 '24	Buy	0.87	150,010	130,899	27,849,880	Jan 08 09:10 AM
PFENNIGER RICHARD C JR	Director	Jan 05 '24	Buy	0.94	25,000	23,429	325,000	Jan 05 12:42 PM
PAGANELLI JOHN A	Director	Jan 05 '24	Buy	0.88	25,000	22,080	384,340	Jan 05 04:00 PM
Rubin Steven D	Executive VP-Administration	Jan 05 '24	Buy	0.87	10,000	8,669	6,187,732	Jan 05 01:39 PM
PFENNIGER RICHARD C JR	Director	Nov 13 '23	Buy	1.30	25,000	32,491	300,000	Nov 14 07:10 AM
FROST PHILLIP MD ET AL	CEO & Chairman	Nov 10 '23	Buy	1.25	500,000	625,462	201,956,694	Nov 13 08:23 AM
HSIAO JANE PH D	Vice Chairman & CTO	Nov 10 '23	Buy	1.27	100,000	126,659	27,699,870	Nov 13 08:21 AM
Rubin Steven D	Executive VP-Administration	Nov 10 '23	Buy	1.30	10,000	13,000	6,177,732	Nov 13 08:21 AM
FROST PHILLIP MD ET AL	CEO & Chairman	Nov 09 '23	Buy	1.28	500,000	641,471	201,456,694	Nov 13 08:23 AM
FROST PHILLIP MD ET AL	CEO & Chairman	Aug 17 '23	Buy	1.76	100,000	175,804	200,956,694	Aug 18 07:10 AM
FROST PHILLIP MD ET AL	CEO & Chairman	Aug 14 '23	Buy	1.75	75,000	131,260	200,856,694	Aug 15 07:05 AM
FROST PHILLIP MD ET AL	CEO & Chairman	Aug 09 '23	Buy	1.82	100,000	181,752	200,781,694	Aug 10 06:59 AM
FROST PHILLIP MD ET AL	CEO & Chairman	Aug 07 '23	Buy	1.84	650,000	1,194,998	200,681,694	Aug 08 07:07 AM
Nabel Gary J.	Chief Innovation Officer	May 05 '23	Buy	1.84	272,637	500,857	19,912,459	May 08 07:03 AM
Nabel Gary J.	Chief Innovation Officer	May 05 '23	Buy	1.81	187,608	340,042	263,079	May 08 07:03 AM

Open in Screener

BCDA

BioCardia Inc.

May 03 • 09:55AM ET

0.3848

Dollar change +0.0098
Percentage change 2.61	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-0.55	Insider Own	35.70%	Shs Outstand	23.67M	Perf Week	2.18%
Market Cap	10.34M	Forward P/E	-	EPS next Y	-	Insider Trans	-0.19%	Shs Float	17.28M	Perf Month	-0.05%
Income	-11.57M	PEG	-	EPS next Q	-	Inst Own	7.75%	Short Float	1.57%	Perf Quarter	-9.86%
Sales	0.48M	P/S	21.54	EPS this Y	-	Inst Trans	-11.46%	Short Ratio	0.76	Perf Half Y	1.56%
Book/sh	-0.07	P/B	-	EPS next Y	-	ROA	-181.08%	Short Interest	0.27M	Perf Year	-80.76%
Cash/sh	0.04	P/C	9.40	EPS next 5Y	-	ROE	-703.62%	52W Range	0.32 - 2.92	Perf YTD	-42.07%
Dividend Est.	-	P/FCF	-	EPS past 5Y	30.13%	ROI	-	52W High	-86.82%	Beta	1.46
Dividend TTM	-	Quick Ratio	0.40	Sales past 5Y	100.50%	Gross Margin	13.84%	52W Low	20.25%	ATR (14)	0.02
Dividend Ex-Date	-	Current Ratio	0.40	EPS Y/Y TTM	18.53%	Oper. Margin	-2441.09%	RSI (14)	49.62	Volatility	5.45% 5.49%
Employees	20	Debt/Eq	-	Sales Y/Y TTM	-64.72%	Profit Margin	-2425.79%	Recom	2.00	Target Price	4.00
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	46.97%	Payout	-	Rel Volume	0.38	Prev Close	0.38
Sales Surprise	-91.05%	EPS Surprise	-20.00%	Sales Q/Q	-87.74%	Earnings	Mar 27 AMC	Avg Volume	358.98K	Price	0.38
SMA20	1.82%	SMA50	-5.63%	SMA200	-32.50%	Trades		Volume	15,944	Change	2.61%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-16-21	Downgrade	Dawson James	Buy → Neutral

May-01-24 07:00AM	BioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes (GlobeNewswire)
Apr-25-24 09:00AM	BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort (GlobeNewswire)
Apr-02-24 05:41PM	Insiders Are Buying These 11 Penny Stocks (Insider Monkey)
Apr-01-24 02:30PM	BioCardia, Inc. (NASDAQ:BCDA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-28-24 05:58AM	Q4 2023 BioCardia Inc Earnings Call (Thomson Reuters StreetEvents)
08:53PM	Loading…
Mar-27-24 08:53PM	BCDA Stock Earnings: BioCardia Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:00PM	BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results (GlobeNewswire)
Mar-20-24 07:00AM	BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024 (GlobeNewswire)
Mar-13-24 07:00AM	BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership (GlobeNewswire)
Mar-12-24 07:00AM	BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study (GlobeNewswire) -9.49%
Mar-04-24 09:27AM	BioCardia rejigs phase 3 heart failure data to find a path forward for cell therapy (FierceBiotech.com) -21.51%
08:00AM	BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure (GlobeNewswire)
Feb-08-24 07:00AM	BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA (GlobeNewswire) -10.34%
Jan-31-24 07:00AM	BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference (GlobeNewswire) -5.66%
Jan-03-24 07:00AM	BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders (GlobeNewswire)
07:00AM	Loading…
Dec-19-23 07:00AM	BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction (GlobeNewswire)
Dec-18-23 07:16AM	BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes (GlobeNewswire) +8.32%
Nov-29-23 07:00AM	BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval (GlobeNewswire)
Nov-16-23 12:56PM	BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules (GlobeNewswire) -15.27%
Nov-15-23 11:04AM	BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study (Zacks) -11.68%
Nov-14-23 07:15AM	BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure (GlobeNewswire) +168.17%
Nov-09-23 12:48PM	BioCardia, Inc. (NASDAQ:BCDA) Q3 2023 Earnings Call Transcript (Insider Monkey) -5.75%
06:59AM	Q3 2023 BioCardia Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-08-23 05:52PM	BioCardia Inc (BCDA) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com) +6.10%
05:50PM	BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:11PM	BioCardia Reports Third Quarter 2023 Business Highlights and Financial Results (GlobeNewswire)
Nov-01-23 05:04PM	BioCardia to Host Q3 2023 Corporate Update and Financial Results Conference Call on November 8, 2023 (GlobeNewswire)
Oct-12-23 11:08AM	BioCardia (BCDA) Up on Plans for Second Heart Failure Study (Zacks) -13.88%
Oct-11-23 06:00AM	BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial II (GlobeNewswire) +28.30%
Sep-06-23 10:31AM	BioCardia (BCDA) Dips 26% on Flunking Heart Failure Study (Zacks) -12.59%
07:15AM	Loading…
07:15AM	BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs (GlobeNewswire)
Sep-05-23 07:15AM	BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial (GlobeNewswire) -25.54%
Aug-11-23 09:29AM	BioCardia, Inc. (NASDAQ:BCDA) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-09-23 06:05PM	BioCardia, Inc. (BCDA) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +6.28%
04:05PM	BioCardia Reports Second Quarter 2023 Business Highlights and Financial Results (GlobeNewswire)
Aug-02-23 07:00AM	BioCardia to Host Q2 2023 Financial Results and Corporate Update Conference Call on August 9, 2023 (GlobeNewswire)
Jul-24-23 07:00AM	BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected (GlobeNewswire) -44.70%
Jul-10-23 08:11AM	Those who invested in BioCardia (NASDAQ:BCDA) a year ago are up 86% (Simply Wall St.)
Jul-05-23 07:00AM	BioCardia Completes Submission of CardiAMP Cell Therapy System in Heart Failure to Japans Pharmaceutical Medical Device Agency (GlobeNewswire)
Jun-20-23 05:14PM	BioCardia Announces FDA Completes Review of Proposed Adaptive Statistical Analysis Design for Ongoing CardiAMP Cell Therapy in Heart Failure Pivotal Study (GlobeNewswire) +6.41%
Jun-08-23 07:00AM	BioCardia Announces Helix Biotherapeutic Delivery Patent Issuance in Japan (GlobeNewswire) +6.53%
May-28-23 08:08AM	Joseph Daly Spends US$177k Buying BioCardia Shares \ (Simply Wall St.)
May-23-23 07:00AM	BioCardia Announces Timing of the Next Data Safety Monitoring Board Meeting for the CardiAMP Cell Therapy in Heart Failure Pivotal Study (GlobeNewswire)
May-12-23 06:06AM	BioCardia First Quarter 2023 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
May-10-23 05:45PM	BioCardia, Inc. (BCDA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	BioCardia Reports First Quarter 2023 Business Highlights and Financial Results (GlobeNewswire)
May-09-23 07:00AM	BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications (GlobeNewswire)
May-03-23 08:00PM	BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023 (GlobeNewswire)
Apr-28-23 07:00AM	BioCardia Presentations at Next Generation Cardiovascular Drug Development Summit Now Available (GlobeNewswire)
Apr-04-23 07:00AM	BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional Therapies (GlobeNewswire)
Apr-01-23 12:47PM	BioCardia, Inc. (NASDAQ:BCDA) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-31-23 06:05AM	We're Keeping An Eye On BioCardia's (NASDAQ:BCDA) Cash Burn Rate (Simply Wall St.)
Mar-29-23 08:15AM	BioCardia Reports Fourth Quarter and Full Year 2022 Business Highlights and Financial Results (GlobeNewswire)
Mar-16-23 07:00AM	BioCardia to Host 2022 Financial Results and Corporate Update Conference Call on March 29, 2023 (GlobeNewswire)
Mar-06-23 01:06PM	BioCardia Outlines Detailed Cell Therapy Data From Heart Failure Study (Benzinga)
07:00AM	Positive Echocardiography Data from BioCardia Phase III CardiAMP Cell Therapy Heart Failure Trial Presented at American College of Cardiology Annual Meeting (GlobeNewswire)
Feb-01-23 06:30AM	BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients (GlobeNewswire) -7.48%
Jan-31-23 05:39AM	Shareholders in BioCardia (NASDAQ:BCDA) are in the red if they invested five years ago (Simply Wall St.)
Dec-22-22 07:00AM	BioCardia Letter to Shareholders (GlobeNewswire)
Dec-21-22 05:07AM	Insider Buying: The BioCardia, Inc. (NASDAQ:BCDA) Independent Director Just Bought 14% More Shares (Simply Wall St.) +6.55%
Dec-15-22 07:00AM	BioCardia Announces $3.6 Million Private Placement of Common Stock (GlobeNewswire)
Dec-06-22 07:00AM	BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure (Business Wire)
Nov-09-22 05:35PM	BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	BioCardia Reports Third Quarter 2022 Business Highlights and Financial Results (GlobeNewswire)
12:00PM	BioCardia, Inc. (BCDA) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-02-22 05:31PM	BioCardia to Host Q3 2022 Financial Results and Corporate Update Conference Call on November 9, 2022 (GlobeNewswire)
Oct-03-22 01:33PM	BioCardia's Heart Failure Cell Therapy Shows 100% Survival At Two Years (Benzinga) +5.67%
07:00AM	BioCardia Presents Positive CardiAMP Cell Therapy Heart Failure Trial Two-Year Data at HFSA Annual Meeting (GlobeNewswire)
Sep-14-22 07:00AM	CardiAMP Cell Therapy Heart Failure Trial Two Year Roll-In Cohort Data to be Presented at Heart Failure Society of America Annual Meeting (GlobeNewswire)
Sep-09-22 07:00AM	BioCardia Announces Participation at H.C. Wainwright Global Investment Conference September 12-14, 2022 (HYBRID CONFERENCE) (GlobeNewswire)
Sep-08-22 07:00AM	BioCardia to Participate in Cantor Fitzgeralds Cell and Genetic Medicines Conference (GlobeNewswire)
Sep-06-22 11:03AM	Here's Why We're Watching BioCardia's (NASDAQ:BCDA) Cash Burn Situation (Simply Wall St.) -5.26%
Aug-31-22 07:00AM	BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial (GlobeNewswire)
Aug-24-22 09:40AM	Has BioCardia (BCDA) Outpaced Other Medical Stocks This Year? (Zacks)
07:00AM	BioCardia Enters Agreement with BlueRock Therapeutics to Provide Enabling Catheter Biotherapeutic Delivery Product Candidates for BlueRocks Cell Therapy to Treat Heart Failure (GlobeNewswire)
Aug-10-22 05:15PM	BioCardia, Inc. (BCDA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:30PM	Edited Transcript of BCDA.OQ earnings conference call or presentation 10-Aug-22 8:30pm GMT (Thomson Reuters StreetEvents)
04:05PM	BioCardia Reports Second Quarter 2022 Business Highlights And Financial Results (GlobeNewswire)
Aug-04-22 02:04PM	BioCardia to Host Q2 2022 Financial Results and Corporate Update Conference Call on August 10, 2022 (GlobeNewswire) +5.88%
Aug-01-22 08:00AM	BioCardia Announces First Canadian Clinical Site for CardiAMP Cell Therapy Heart Failure Trial (GlobeNewswire)
Jul-12-22 08:15AM	BioCardia to Participate in Upcoming Heart and Pulmonary Therapy Development Symposia (GlobeNewswire)
Jun-15-22 08:00AM	BioCardia Announces US Patent on Imaging System for Targeting Cardiac Therapies (GlobeNewswire)
May-11-22 05:55PM	BioCardia, Inc. (BCDA) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -11.94%
04:15PM	BioCardia Reports First Quarter 2022 Business Highlights and Financial Results (GlobeNewswire)
May-06-22 03:15PM	Follow the Insiders and Buy the Dip in These 3 Stocks (InvestorPlace)
May-04-22 08:30AM	BioCardia to Host Q1 2022 Financial Results and Corporate Update Conference Call on May 11, 2022 (GlobeNewswire)
Apr-13-22 10:25AM	BioCardia (BCDA) Gains FDA Nod for ARDS Cell Therapy Study (Zacks) -13.07%
Apr-12-22 07:15AM	BioCardia Announces FDA Approval of Its IND for NK1R+ Mesenchymal Stem Cells for the Treatment of Patients Recovering from Acute Respiratory Distress due to COVID-19 (GlobeNewswire) -7.44%
Mar-30-22 03:51PM	Here's Why We're Watching BioCardia's (NASDAQ:BCDA) Cash Burn Situation (Simply Wall St.)
Mar-29-22 04:05PM	BioCardia Reports 2021 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-24-22 08:00AM	BioCardia to Host 2021 Financial Results and Corporate Update Conference Call on March 29, 2022 (GlobeNewswire)
Mar-22-22 08:30AM	BioCardia Announces New Center for Medicare and Medicaid Services Reimbursement Code Applicable to the CardiAMP Cell Therapy Procedure (GlobeNewswire)
Mar-01-22 08:00AM	BioCardia Receives No Objection Letter from Health Canada, Enabling Company to Expand CardiAMP Cell Therapy Heart Failure Trial into Canada (GlobeNewswire) +5.80%
Feb-14-22 07:30AM	BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Study as Designed (GlobeNewswire) -12.30%
Feb-03-22 02:53PM	Why Are BioCardia Shares Trading Higher Today? (Benzinga) +27.39%
08:00AM	BioCardia Receives FDA Breakthrough Device Designation for CardiAMP Cell Therapy System for Heart Failure (Business Wire)
Jan-10-22 08:00AM	BioCardia Announces Participation at the Upcoming Digital Medicine & Medtech Showcase and the H.C. Wainwright BioConnect Virtual Conference (GlobeNewswire)
Dec-15-21 08:00AM	BioCardia Establishes New Manufacturing Facility to Enable Its Cell Therapy Product Candidates (GlobeNewswire)
Nov-10-21 04:30PM	BioCardia Reports Third Quarter 2021 Financial Results and Business Highlights (GlobeNewswire)
Nov-08-21 04:30PM	BioCardia To Release Third Quarter 2021 Financial Results November 10, 2021 (GlobeNewswire)

BioCardia, Inc. is a clinical-stage biotherapeutic company. It engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Altman Peter	President and CEO	Apr 19 '24	Buy	0.37	2,750	1,013	558,697	Apr 19 05:38 PM
Altman Peter	President and CEO	Mar 28 '24	Buy	0.39	500	195	555,947	Mar 28 07:33 PM
Altman Peter	President and CEO	Feb 13 '24	Buy	0.46	108,108	50,000	555,447	Feb 15 07:00 AM
FROST PHILLIP MD ET AL	10% Owner	Jan 19 '24	Sale	0.43	129,802	55,815	1,896,025	Jan 22 08:38 PM
Altman Peter	President and CEO	May 26 '23	Buy	1.60	6,200	9,920	469,239	May 30 05:01 PM

Open in Screener

FLNT

Fluent Inc

May 03 • 09:58AM ET

3.39

Dollar change +0.07
Percentage change 2.11	%

Communication Services • Advertising Agencies • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF BSVO DFAT

Index	-	P/E	-	EPS (ttm)	-4.60	Insider Own	49.03%	Shs Outstand	13.55M	Perf Week	14.92%
Market Cap	46.10M	Forward P/E	37.67	EPS next Y	0.09	Insider Trans	8.42%	Shs Float	6.93M	Perf Month	9.86%
Income	-63.22M	PEG	-	EPS next Q	-0.15	Inst Own	24.58%	Short Float	1.38%	Perf Quarter	-5.68%
Sales	298.40M	P/S	0.15	EPS this Y	83.33%	Inst Trans	-	Short Ratio	3.05	Perf Half Y	16.16%
Book/sh	2.54	P/B	1.34	EPS next Y	200.00%	ROA	-42.74%	Short Interest	0.10M	Perf Year	-21.98%
Cash/sh	1.16	P/C	2.92	EPS next 5Y	40.00%	ROE	-98.50%	52W Range	2.31 - 4.78	Perf YTD	-15.67%
Dividend Est.	-	P/FCF	6.08	EPS past 5Y	-	ROI	-102.64%	52W High	-29.02%	Beta	2.32
Dividend TTM	-	Quick Ratio	1.59	Sales past 5Y	4.23%	Gross Margin	22.67%	52W Low	46.79%	ATR (14)	0.26
Dividend Ex-Date	-	Current Ratio	1.59	EPS Y/Y TTM	49.25%	Oper. Margin	-2.63%	RSI (14)	64.27	Volatility	8.70% 9.30%
Employees	277	Debt/Eq	1.00	Sales Y/Y TTM	-17.37%	Profit Margin	-21.19%	Recom	3.00	Target Price	12.00
Option/Short	No / Yes	LT Debt/Eq	0.79	EPS Q/Q	97.23%	Payout	-	Rel Volume	0.61	Prev Close	3.32
Sales Surprise	-1.78%	EPS Surprise	100.00%	Sales Q/Q	-14.06%	Earnings	Apr 02 AMC	Avg Volume	31.36K	Price	3.39
SMA20	18.71%	SMA50	13.30%	SMA200	1.62%	Trades		Volume	2,259	Change	2.11%

Date	Action	Analyst	Rating Change	Price Target Change
May-10-22	Upgrade	Barrington Research	Mkt Perform → Outperform	$2.50
Mar-17-21	Downgrade	Barrington Research	Outperform → Mkt Perform
Nov-02-20	Upgrade	Barrington Research	Mkt Perform → Outperform	$4.50
Aug-26-20	Initiated	Canaccord Genuity	Buy	$5
Nov-12-19	Downgrade	Barrington Research	Outperform → Mkt Perform
May-09-19	Upgrade	ROTH Capital	Neutral → Buy	$5.50 → $8.50

May-02-24 07:00AM	SLR Credit Solutions Agents Senior Credit Facility for Fluent, Inc. (Business Wire)
Apr-10-24 08:00AM	Fluent Announces Reverse Stock Split (GlobeNewswire)
Apr-03-24 09:00AM	Influencer Media Group Infuse Follows Up on Stellar 2023 Growth with New Partnership, Podcast Launch, and Influencer Events (GlobeNewswire)
06:44AM	Q4 2023 Fluent Inc Earnings Call (Thomson Reuters StreetEvents)
Apr-02-24 05:32PM	Fluent Announces Fourth Quarter and Full-Year 2023 Financial Results (GlobeNewswire)
10:48PM	Loading…
Apr-01-24 10:48PM	Fluent, Inc. to Announce Fourth Quarter and Full-Year 2023 Financial Results on April 2, 2024 (GlobeNewswire)
Mar-21-24 09:00AM	Fluent Partners with Fyllo Semasio to Expand Audience Solutions with Contextual Offering (GlobeNewswire)
Feb-29-24 02:25PM	Fluent (FLNT) Reports Break-Even Earnings for Q4 (Zacks) +9.44%
12:22PM	Fluent Announces Expected Fourth Quarter and Full-Year 2023 Financial Results (GlobeNewswire)
Feb-27-24 09:00AM	New Fluent Survey of Retailers and Brands Measures Commerce Media Strategies and Challenges (GlobeNewswire) -5.51%
Jan-25-24 08:30AM	Fluent Secures Top Spot as the #1 Digital Agency in Ad Age's 2024 Best Places to Work List (GlobeNewswire)
Nov-15-23 09:55AM	Q3 2023 Fluent Inc Earnings Call (Thomson Reuters StreetEvents) -16.50%
Nov-14-23 05:11PM	UPDATE - Fluent Announces Third Quarter 2023 Financial Results (GlobeNewswire) +6.64%
04:54PM	Fluent: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Fluent Announces Third Quarter 2023 Financial Results (GlobeNewswire)
03:00PM	Loading…
Nov-03-23 03:00PM	Fluent, Inc. to Announce Third Quarter Financial Results on November 14, 2023 (GlobeNewswire) +5.55%
Aug-22-23 08:30AM	Fluent, Inc. Launches Infuse Influencer Platform to Unlock New Customer Acquisition Opportunities for Advertisers (GlobeNewswire)
Aug-15-23 12:04PM	Fluent, Inc. (NASDAQ:FLNT) Q2 2023 Earnings Call Transcript (Insider Monkey)
06:05AM	Q2 2023 Fluent Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-14-23 04:30PM	Fluent Announces Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-09-23 09:09PM	7 Stocks That Could Triple Your Money by 2024 (InvestorPlace)
Aug-08-23 08:30AM	Fluent Launches Post-Transaction Ecommerce Advertising Solution (GlobeNewswire)
Aug-02-23 08:30AM	AdParlor Introduces CreatorFuel: A Full-Funnel Influencer Marketing Solution (GlobeNewswire)
Aug-01-23 03:30PM	Fluent, Inc. to Announce Second Quarter Financial Results on August 14, 2023 (GlobeNewswire)
Jul-27-23 08:30AM	Fluent, Inc.'s 2023 Mobile Gaming Survey Reveals Generational Insights into Gamers' Behavior and Preferences (GlobeNewswire)
Jul-10-23 10:14AM	Several Insiders Invested In Fluent Flagging Positive News (Simply Wall St.)
Jun-13-23 08:42AM	Investors in Fluent (NASDAQ:FLNT) have unfortunately lost 77% over the last five years (Simply Wall St.)
May-17-23 06:15AM	Investors Will Want Fluent's (NASDAQ:FLNT) Growth In ROCE To Persist (Simply Wall St.)
May-16-23 08:01AM	Q1 2023 Fluent Inc Earnings Call (Thomson Reuters StreetEvents) -20.19%
May-15-23 04:15PM	Fluent Announces First Quarter 2023 Financial Results (GlobeNewswire)
02:10PM	Loading…
May-12-23 02:10PM	Fluent (FLNT) to Post Q1 Earnings: What's in the Offing? (Zacks)
May-11-23 09:40AM	Should Value Investors Buy Fluent (FLNT) Stock? (Zacks)
May-02-23 05:50PM	Fluent (FLNT) Stock Moves -0.67%: What You Should Know (Zacks)
08:30AM	Fluent, Inc. to Announce First Quarter Financial Results on May 15, 2023 (GlobeNewswire)
May-01-23 09:00AM	Here is What to Know Beyond Why FLUENT, INC. (FLNT) is a Trending Stock (Zacks)
Apr-26-23 05:50PM	Fluent (FLNT) Stock Moves -0.16%: What You Should Know (Zacks)
Apr-20-23 05:50PM	Fluent (FLNT) Flat As Market Sinks: What You Should Know (Zacks)
Apr-18-23 10:02AM	Investors Aren't Entirely Convinced By Fluent, Inc.'s (NASDAQ:FLNT) Revenues (Simply Wall St.)
09:00AM	Is Trending Stock FLUENT, INC. (FLNT) a Buy Now? (Zacks)
Apr-07-23 09:35AM	After Plunging -50.86% in 4 Weeks, Here's Why the Trend Might Reverse for Fluent (FLNT) (Zacks)
Apr-06-23 08:30AM	Fluent Maintains #1 Ranking for Data Accuracy in Latest Truthset Truthscore Index (GlobeNewswire) -6.63%
Apr-05-23 09:40AM	Is Fluent (FLNT) Stock Undervalued Right Now? (Zacks) -6.16%
Mar-20-23 09:40AM	Should Value Investors Buy Fluent (FLNT) Stock? (Zacks)
05:33AM	Best Value Stocks to Buy for March 20th (Zacks)
Mar-18-23 03:12AM	Fluent, Inc. (NASDAQ:FLNT) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-17-23 06:16AM	Fluent Full Year 2022 Earnings: Misses Expectations (Simply Wall St.) -9.43%
Mar-16-23 05:53AM	Q4 2022 Fluent Inc Earnings Call (Thomson Reuters StreetEvents) -32.63%
Mar-15-23 04:15PM	Fluent Announces Fourth Quarter and Full-Year 2022 Financial Results (GlobeNewswire)
Feb-27-23 09:00AM	Fluent, Inc. to Announce Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 (GlobeNewswire)
Feb-08-23 09:40AM	Are Investors Undervaluing Fluent (FLNT) Right Now? (Zacks)
Jan-25-23 05:50AM	A number of insiders bought Fluent, Inc. (NASDAQ:FLNT) stock last year, which is great news for shareholders (Simply Wall St.)
Jan-20-23 09:40AM	Is Fluent (FLNT) Stock Undervalued Right Now? (Zacks)
Jan-15-23 03:10PM	13 Cash-Rich Penny Stocks Hedge Funds Are Buying (Insider Monkey)
Dec-22-22 07:38AM	The past five years for Fluent (NASDAQ:FLNT) investors has not been profitable (Simply Wall St.)
Nov-07-22 04:01PM	Fluent Announces Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-26-22 08:30AM	Fluent, Inc. to Announce Third Quarter Financial Results on November 7, 2022 (GlobeNewswire) +6.50%
Oct-19-22 07:53AM	Fluent, Inc. (NASDAQ:FLNT) boasts of bullish insider sentiment with 41% ownership and they have been buying lately (Simply Wall St.)
Oct-17-22 08:30AM	Fluent, Inc. Data is Now Available in TransUnion's TruAudience® Data Marketplace to Enable Enhanced Targeting Capabilities (GlobeNewswire)
Oct-11-22 08:30AM	Fluent, Inc. Appoints David A. Graff and Richard C. Pfenniger, Jr. to Board of Directors (GlobeNewswire)
Oct-05-22 08:30AM	Fluent Launches Purpose to Empower Consumer Financial Decisions (GlobeNewswire)
Sep-14-22 06:30AM	7 Kim Kardashian Stocks to Buy (InvestorPlace)
Sep-13-22 08:30AM	Fluent Ranks #1 for Data Quality and Accuracy in Q2 2022 Truthset Truthscore Index (GlobeNewswire)
Aug-18-22 06:16AM	Insider Buying: The Fluent, Inc. (NASDAQ:FLNT) Co-Founder Just Bought 1.3% More Shares (Simply Wall St.)
Aug-09-22 08:00PM	Fluent, Inc (FLNT) Q2 2022 Earnings Call Transcript (Motley Fool) -8.16%
05:55PM	Fluent (FLNT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:30PM	Edited Transcript of FLNT.OQ earnings conference call or presentation 9-Aug-22 8:30pm GMT (Thomson Reuters StreetEvents)
04:01PM	Fluent, Inc. Announces Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-08-22 11:30AM	Fluent, Inc. to Present at the Canaccord Genuity 42nd Annual Growth Conference (GlobeNewswire) +22.50%
Aug-04-22 05:51PM	Fluent, Inc. to Announce Second Quarter Financial Results on August 9, 2022 (GlobeNewswire)
Jul-22-22 08:50AM	Fluent (FLNT) Shows Fast-paced Momentum But Is Still a Bargain Stock (Zacks)
Jul-15-22 06:10AM	Shareholders in Fluent (NASDAQ:FLNT) are in the red if they invested three years ago (Simply Wall St.)
May-25-22 09:00AM	Fluent, Inc. to Host 2022 Annual Meeting of Shareholders (GlobeNewswire)
May-13-22 04:06PM	Fluent, Inc. to Present at the 17th Annual Needham Technology & Media Conference (GlobeNewswire) -6.21%
May-12-22 06:44AM	Is Fluent, Inc. (NASDAQ:FLNT) Popular Amongst Insiders? (Simply Wall St.)
May-09-22 09:00PM	Fluent, Inc (FLNT) Q1 2022 Earnings Call Transcript (Motley Fool)
06:25PM	Fluent (FLNT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:04PM	Fluent Announces First Quarter 2022 Financial Results (GlobeNewswire)
May-02-22 03:00PM	Fluent (FLNT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Apr-28-22 12:00PM	Fluent, Inc. to Announce First Quarter Financial Results on May 9, 2022 (GlobeNewswire)
09:00AM	Fluent Appoints Melanie Murphy as Chief Analytics Officer (GlobeNewswire)
Apr-19-22 09:00AM	Fluent Partners with Cadent to Launch Audience Segments for Advanced TV Marketing Initiatives (GlobeNewswire) +7.10%
Mar-23-22 09:00AM	Fluent Recognized as #1 Growth Partner in AppsFlyer Performance Index 14 (GlobeNewswire) -5.91%
Mar-22-22 09:00AM	Fluent Joins DeepIntents Audience Marketplace with Permissioned Data for Healthcare Marketers (GlobeNewswire)
Mar-21-22 09:30AM	Fluent Expands Growth Opportunities for Brand Partners with Mobile App Studio (GlobeNewswire)
Mar-08-22 08:30PM	Fluent, Inc (FLNT) Q4 2021 Earnings Call Transcript (Motley Fool)
05:45PM	Fluent (FLNT) Matches Q4 Earnings Estimates (Zacks)
04:20PM	Fluent Announces Fourth Quarter and Full-Year 2021 Financial Results (GlobeNewswire)
Mar-02-22 08:30AM	CORRECTION: Fluent, Inc. to Announce Fourth Quarter and Full-Year 2021 Financial Results on March 8, 2022 (GlobeNewswire) +5.04%
Mar-01-22 08:30AM	Fluent, Inc. to Announce Fourth Quarter and Full-Year Financial Results on March 8, 2021 (GlobeNewswire)
Jan-03-22 05:24AM	Shareholders in Fluent (NASDAQ:FLNT) have lost 63%, as stock drops 12% this past week (Simply Wall St.) +6.03%
Nov-15-21 08:30AM	Fluent, Inc. to Appoint Walmart Executive Sugandha Khandelwal as Chief Financial Officer (GlobeNewswire)
Nov-05-21 04:01PM	Fluent, Inc (FLNT) Q3 2021 Earnings Call Transcript (Motley Fool)
Nov-04-21 08:56PM	Fluent (FLNT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:15PM	Fluent Announces Third Quarter 2021 Financial Results (GlobeNewswire)
Oct-29-21 09:00AM	Fluent Recognized as Mobile Gaming Leader in 2021 AppsFlyer Performance Index XIII (GlobeNewswire)
Oct-28-21 04:30PM	Fluent, Inc. to Announce Third Quarter 2021 Financial Results on November 4, 2021 (GlobeNewswire)
Oct-08-21 09:23AM	Fluent Ranked in Five Leading Categories in Adjusts First-Ever Partner Benchmarks Report (GlobeNewswire)
Oct-05-21 09:00AM	Fluents Authenticated Consumer Data Now Available Through Snowflake Data Marketplace (GlobeNewswire)
08:30AM	Here's What Fluent, Inc.'s (NASDAQ:FLNT) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Sep-07-21 09:00AM	Fluent Strengthens Customer Acquisition Capabilities for its Growing Roster of Global Brands with Full Acquisition of Winopoly, LLC (GlobeNewswire) +5.88%

Fluent, Inc. engages in the provision of digital marketing services. It operates through the Fluent and All Other segments. The Fluent segment includes delivering data and performance-based marketing executions. The All Other segment represents the operation results of AdParlor, LLC, a digital advertising solution for social media buying. The company was founded by Ryan Schulke and Matthew Conlin in 2001 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schulke Ryan	Chief Strategy Officer	Mar 14 '24	Buy	0.53	21,000	11,128	600,159	Mar 14 05:57 PM
Schulke Ryan	Chief Strategy Officer	Mar 13 '24	Buy	0.53	10,000	5,299	579,159	Mar 14 05:57 PM
Schulke Ryan	Chief Strategy Officer	Mar 12 '24	Buy	0.59	20,000	11,858	569,159	Mar 12 06:17 PM
Perfit Ryan MacNab	Interim CFO	Mar 11 '24	Buy	0.58	10,000	5,787	45,596	Mar 12 06:26 PM
Schulke Ryan	Chief Strategy Officer	Mar 08 '24	Buy	0.62	10,000	6,187	549,159	Mar 11 09:43 PM
Perfit Ryan MacNab	Interim CFO	Mar 08 '24	Buy	0.57	596	340	35,596	Mar 12 06:26 PM
Schulke Ryan	Chief Strategy Officer	Mar 07 '24	Buy	0.59	10,000	5,900	539,159	Mar 07 05:43 PM
Schulke Ryan	Chief Strategy Officer	Mar 06 '24	Buy	0.52	10,000	5,201	529,159	Mar 06 06:25 PM
Schulke Ryan	Chief Strategy Officer	Mar 05 '24	Buy	0.53	10,000	5,336	519,159	Mar 06 06:25 PM
Schulke Ryan	Chief Strategy Officer	Mar 04 '24	Buy	0.60	10,000	5,973	509,159	Mar 06 06:25 PM
Perfit Ryan MacNab	Interim CFO	Mar 04 '24	Buy	0.59	10,000	5,900	35,000	Mar 06 06:25 PM
Schulke Ryan	Chief Strategy Officer	Dec 14 '23	Buy	0.58	12,000	6,922	499,159	Dec 18 05:58 PM
Conlin Matthew	Chief Customer Officer	Dec 14 '23	Buy	0.58	5,000	2,880	211,970	Dec 18 05:57 PM
Schulke Ryan	Chief Strategy Officer	Dec 13 '23	Buy	0.53	10,659	5,611	487,159	Dec 14 10:23 AM
Schulke Ryan	Chief Strategy Officer	Dec 12 '23	Buy	0.51	12,000	6,107	476,500	Dec 14 10:23 AM
Conlin Matthew	Chief Customer Officer	Dec 12 '23	Buy	0.51	5,000	2,544	206,970	Dec 14 10:28 AM
Schulke Ryan	Chief Strategy Officer	Dec 11 '23	Buy	0.51	12,000	6,077	464,500	Dec 12 09:54 AM
Schulke Ryan	Chief Strategy Officer	Dec 08 '23	Buy	0.51	12,000	6,065	452,500	Dec 12 09:54 AM
Conlin Matthew	Chief Customer Officer	Dec 08 '23	Buy	0.50	4,500	2,272	201,970	Dec 12 09:57 AM
Schulke Ryan	Chief Strategy Officer	Dec 07 '23	Buy	0.50	12,000	6,044	440,500	Dec 08 02:50 PM
Schulke Ryan	Chief Strategy Officer	Dec 06 '23	Buy	0.50	12,000	6,030	428,500	Dec 08 02:50 PM
Schulke Ryan	Chief Strategy Officer	Dec 05 '23	Buy	0.51	12,000	6,074	416,500	Dec 05 06:13 PM
Perfit Ryan MacNab	Interim CFO	Dec 05 '23	Buy	0.50	10,000	5,000	25,000	Dec 07 08:46 AM
Schulke Ryan	Chief Strategy Officer	Dec 04 '23	Buy	0.52	12,000	6,208	404,500	Dec 05 06:13 PM
Conlin Matthew	Chief Customer Officer	Dec 04 '23	Buy	0.52	5,000	2,586	197,470	Dec 07 08:44 AM
Schulke Ryan	Chief Strategy Officer	Dec 01 '23	Buy	0.52	12,000	6,206	392,500	Dec 05 06:13 PM
Schulke Ryan	Chief Strategy Officer	Nov 30 '23	Buy	0.52	12,000	6,246	380,500	Nov 30 09:01 PM
Schulke Ryan	Chief Strategy Officer	Nov 29 '23	Buy	0.50	12,000	6,052	368,500	Nov 30 09:01 PM
Conlin Matthew	Chief Customer Officer	Nov 29 '23	Buy	0.51	3,700	1,869	192,470	Nov 30 08:59 PM
Schulke Ryan	Chief Strategy Officer	Nov 28 '23	Buy	0.51	12,000	6,108	356,500	Nov 30 09:01 PM
Conlin Matthew	Chief Customer Officer	Nov 28 '23	Buy	0.51	3,700	1,886	188,770	Nov 30 08:59 PM
Schulke Ryan	Chief Strategy Officer	Nov 27 '23	Buy	0.51	12,000	6,104	344,500	Nov 27 06:32 PM
Conlin Matthew	Chief Customer Officer	Nov 27 '23	Buy	0.51	3,700	1,885	185,070	Nov 27 06:25 PM
Schulke Ryan	Chief Strategy Officer	Nov 24 '23	Buy	0.51	12,000	6,116	332,500	Nov 27 06:32 PM
Conlin Matthew	Chief Customer Officer	Nov 24 '23	Buy	0.51	3,800	1,937	181,370	Nov 27 06:25 PM
Schulke Ryan	Chief Strategy Officer	Nov 22 '23	Buy	0.51	12,000	6,139	320,500	Nov 27 06:32 PM
Conlin Matthew	Chief Customer Officer	Nov 22 '23	Buy	0.51	5,000	2,560	177,570	Nov 27 06:25 PM
Schulke Ryan	Chief Strategy Officer	Nov 21 '23	Buy	0.53	12,000	6,358	308,500	Nov 21 09:23 PM
Conlin Matthew	Chief Customer Officer	Nov 21 '23	Buy	0.53	5,000	2,638	172,570	Nov 21 09:28 PM
Schulke Ryan	Chief Strategy Officer	Nov 20 '23	Buy	0.54	12,000	6,460	296,500	Nov 21 09:23 PM
Conlin Matthew	Chief Customer Officer	Nov 20 '23	Buy	0.52	10,000	5,200	167,570	Nov 21 09:28 PM
Schulke Ryan	Chief Strategy Officer	Nov 17 '23	Buy	0.52	12,000	6,247	284,500	Nov 21 09:23 PM
Conlin Matthew	Chief Customer Officer	Nov 17 '23	Buy	0.52	10,000	5,200	157,570	Nov 21 09:28 PM
FROST PHILLIP MD ET AL	10% Owner	Sep 19 '23	Buy	0.46	100,000	46,000	18,834,874	Sep 21 04:44 PM
Schulke Ryan	Chief Strategy Officer	May 19 '23	Buy	0.70	40,000	27,812	272,500	May 23 01:24 PM
Conlin Matthew	Chief Customer Officer	May 19 '23	Buy	0.68	40,000	27,168	147,570	May 30 07:40 PM
Perfit Ryan MacNab	Interim CFO	May 18 '23	Buy	0.67	15,000	9,999	15,000	May 26 02:34 PM
Patrick Donald Huntley	Chief Executive Officer	May 18 '23	Buy	0.65	4,800	3,134	1,600,911	May 22 07:27 PM

Open in Screener

COCP

Cocrystal Pharma Inc

May 03 • 09:34AM ET

1.54

Dollar change -0.05
Percentage change -3.01	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

COCP Cocrystal Pharma Inc daily Stock Chart

Held by: VTI VXF

Index	-	P/E	-	EPS (ttm)	-1.90	Insider Own	30.03%	Shs Outstand	10.17M	Perf Week	-0.82%
Market Cap	15.68M	Forward P/E	-	EPS next Y	-1.96	Insider Trans	0.00%	Shs Float	7.12M	Perf Month	4.91%
Income	-17.98M	PEG	-	EPS next Q	-0.54	Inst Own	6.72%	Short Float	0.02%	Perf Quarter	-4.21%
Sales	0.00M	P/S	-	EPS this Y	-22.73%	Inst Trans	-2.52%	Short Ratio	0.11	Perf Half Y	-8.20%
Book/sh	2.59	P/B	0.59	EPS next Y	14.81%	ROA	-49.89%	Short Interest	0.00M	Perf Year	-39.04%
Cash/sh	2.60	P/C	0.59	EPS next 5Y	-	ROE	-54.54%	52W Range	1.33 - 3.29	Perf YTD	-10.45%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-1.25%	ROI	-64.24%	52W High	-53.05%	Beta	1.30
Dividend TTM	-	Quick Ratio	8.92	Sales past 5Y	-33.86%	Gross Margin	-	52W Low	16.39%	ATR (14)	0.09
Dividend Ex-Date	-	Current Ratio	8.92	EPS Y/Y TTM	84.77%	Oper. Margin	0.00%	RSI (14)	51.98	Volatility	4.16% 6.30%
Employees	12	Debt/Eq	0.07	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	8.00
Option/Short	No / Yes	LT Debt/Eq	0.06	EPS Q/Q	20.61%	Payout	-	Rel Volume	0.02	Prev Close	1.59
Sales Surprise	-	EPS Surprise	46.37%	Sales Q/Q	-	Earnings	Mar 29 BMO	Avg Volume	13.77K	Price	1.54
SMA20	1.05%	SMA50	3.02%	SMA200	-17.58%	Trades		Volume	38	Change	-3.01%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-08-20	Initiated	H.C. Wainwright	Buy	$5

May-01-24 08:00AM	Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza (GlobeNewswire)
Mar-28-24 01:53PM	COCP Stock Earnings: Cocrystal Pharma Beats EPS for Q4 2023 (InvestorPlace) -6.67%
08:00AM	Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire)
Mar-19-24 08:00AM	Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A (GlobeNewswire)
Mar-05-24 08:30AM	Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap (ACCESSWIRE)
08:00AM	Loading…
Jan-04-24 08:00AM	Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates (GlobeNewswire)
Dec-06-23 08:00AM	Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A (GlobeNewswire)
Nov-29-23 08:00AM	Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast (GlobeNewswire)
Nov-27-23 08:00AM	Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023 (GlobeNewswire) +17.12%
Nov-13-23 08:00AM	Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs (GlobeNewswire)
Nov-09-23 08:00AM	Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast (GlobeNewswire)
Oct-31-23 08:00AM	Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344 (GlobeNewswire) +5.25%
Oct-02-23 12:14PM	COCP: Cocrystal Pharma doses 1st subjects in the important CDI-988 clinical trial. (Zacks)
Sep-28-23 08:00AM	Cocrystal Pharma Doses First Subjects in Clinical Study of CDI-988 For Pandemic Norovirus and Coronavirus (GlobeNewswire)
Sep-05-23 08:00AM	Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference (GlobeNewswire) -8.38%
09:11AM	Loading…
Aug-16-23 09:11AM	COCP: Cocrystal Pharma reports 2nd quarter 2023 financial results and provides updates on drug pipeline. (Zacks)
Aug-14-23 08:00AM	Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs (GlobeNewswire)
Aug-08-23 08:00AM	Cocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 as Norovirus Lead (GlobeNewswire) +7.39%
May-31-23 08:00AM	Cocrystal Pharma Receives HREC Approval to Initiate Phase 1 Study to Evaluate Oral Broad-Spectrum Coronavirus 3CL Protease Inhibitor CDI-988 (GlobeNewswire)
May-17-23 09:26AM	COCP: Cocrystal Pharma reports 1st quarter 2023 financial results and provides updates on drug pipeline. (Zacks Small Cap Research) -5.88%
May-15-23 08:00AM	Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs (GlobeNewswire) -5.28%
May-04-23 04:05PM	Cocrystal Pharma Presents New Data from its CC-42344 Phase 1 Influenza A Study at the 7th Annual ISIRV Antiviral Group Conference (GlobeNewswire)
Apr-24-23 08:00AM	Cocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan to its Board of Directors (GlobeNewswire) +6.05%
Apr-18-23 08:00AM	Cocrystal Pharma to Present New Data from its CC-42344 Phase 1 Influenza A Study at the 7th Annual ISIRV Antiviral Group Conference (GlobeNewswire)
Apr-10-23 08:30AM	Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +12.95%
Mar-31-23 10:05AM	COCP: UPDATE: Cocrystal Pharma announces full year 2022 financial results and provides drug program updates. (Zacks Small Cap Research) +5.85%
Mar-29-23 08:00AM	Cocrystal Pharma Reports 2022 Financial Results and Provides Updates on its Antiviral Drug Development Programs (GlobeNewswire)
Mar-22-23 01:03PM	COCP: UPDATE: Cocrystal Pharma announced several program updates and investor events. (Zacks Small Cap Research)
08:00AM	Cocrystal Pharma to Highlights Progress with Its Antiviral Portfolio at the Virtual Investor Summit on March 29, 2023 (GlobeNewswire)
Jan-26-23 08:00AM	Cocrystal Pharma Announces Participation in Virtual Investor Events (GlobeNewswire) -6.62%
09:00AM	Loading…
Jan-23-23 09:00AM	Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast (Newsfile)
Dec-19-22 08:00AM	Cocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A (GlobeNewswire) -11.39%
Dec-01-22 04:05PM	Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022 (GlobeNewswire)
Nov-17-22 01:38PM	Cocrystal Pharma Posts Favorable Safety Data From Oral Antiviral Against Influenza A (Benzinga)
08:00AM	Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A (GlobeNewswire)
Nov-15-22 11:19AM	COCP: UPDATE: Cocrystal Pharma releases 2022 3rd quarter results and provides an update on the current pipeline programs. (Zacks Small Cap Research)
Nov-14-22 08:00AM	Cocrystal Pharma Reports Third Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs (GlobeNewswire)
Nov-02-22 08:00AM	Cocrystal Pharma to Participate in Two Investor Conferences in November (GlobeNewswire) +13.41%
Nov-01-22 04:05PM	Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of Influenza (GlobeNewswire)
Oct-26-22 08:00AM	Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharmas Oral Antiviral Candidate CC-42344 (GlobeNewswire)
Oct-19-22 08:00AM	Cocrystal Pharma to Present at the LD Micro Main Event XV (GlobeNewswire)
Oct-13-22 08:00AM	Cocrystal Pharma to Present CC-42344 Phase 1 Influenza A Data at the World Antiviral Congress 2022 (GlobeNewswire)
Oct-11-22 11:51AM	Cocrystal Pharma Advances One Of Its COVID-19 Antiviral Treatment Candidate (Benzinga) -9.02%
08:00AM	Cocrystal Pharma Selects CDI-988 for Clinical Development as an Oral Treatment for COVID-19 (GlobeNewswire)
Oct-05-22 08:00AM	Cocrystal Pharma to Present at the Dawson James Securities 2022 Small Cap Growth Conference (GlobeNewswire)
Oct-03-22 04:05PM	Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split (GlobeNewswire)
Sep-06-22 10:05AM	Companies Like Cocrystal Pharma (NASDAQ:COCP) Are In A Position To Invest In Growth (Simply Wall St.)
08:00AM	Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-19-22 08:10AM	COCP: UPDATE: Cocrystal Pharma releases 2022 2nd quarter results and provides an update on the current pipeline programs. (Zacks Small Cap Research) -6.42%
Aug-15-22 08:00AM	Cocrystal Pharma Reports Second Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs (GlobeNewswire)
Aug-08-22 08:00AM	Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344 (GlobeNewswire)
Aug-03-22 09:00AM	Cocrystal Pharma Discusses Therapeutic Platform Applications and Progress with The Stock Day Podcast (Newsfile)
Jul-14-22 08:00AM	Cocrystal Pharma Reports CC-42344 Pharmacokinetic Data in Influenza A Once-Daily Dosing (GlobeNewswire)
Jun-01-22 08:00AM	Cocrystal Pharma Expands Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors (GlobeNewswire)
May-18-22 08:00AM	Cocrystal Pharma to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
May-12-22 08:12AM	COCP: Cocrystal Pharma Releases 2022 1st Quarter Results and Provides an Update on the Current Pipeline Programs (Zacks Small Cap Research)
May-11-22 08:00AM	Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones (GlobeNewswire) -5.02%
Apr-21-22 08:00AM	Cocrystal Pharma Collaborates with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors (GlobeNewswire)
Apr-19-22 08:00AM	Cocrystal Pharma to Present at the Life Science Innovation Northwest 2022 Conference (GlobeNewswire)
Apr-14-22 08:00AM	Cocrystal Pharma to Present at the Noble Capital Markets NobleCon18 Conference (GlobeNewswire)
Apr-12-22 11:01AM	Cocrystal Pharma Posts Favorable Preliminary Data From Influenza A Antiviral Candidate Trial (Benzinga)
08:00AM	Cocrystal Pharma Reports Favorable Preliminary Data from Phase 1 Initial Cohorts with CC-42344, a Novel, Broad-Spectrum Influenza A antiviral (GlobeNewswire)
Apr-06-22 10:15AM	10 Biotech Penny Stocks with Growth Catalysts (Insider Monkey)
Mar-30-22 02:57PM	We're Hopeful That Cocrystal Pharma (NASDAQ:COCP) Will Use Its Cash Wisely (Simply Wall St.)
Mar-25-22 07:30AM	COCP: Cocrystal Pharma releases 2021 fiscal year results and provides an update on the current pipeline programs (Zacks Small Cap Research)
Mar-23-22 04:05PM	Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones (GlobeNewswire)
Mar-22-22 08:00AM	Cocrystal Pharma to Participate in the Maxim Group 2022 Virtual Growth Conference (GlobeNewswire)
Mar-10-22 08:00AM	Cocrystal Pharma Initiates Enrollment in Phase 1 Influenza A Study with Novel, Broad-Spectrum, Orally Administrated Antiviral CC-42344 (GlobeNewswire)
Mar-03-22 08:00AM	Cocrystal Pharma to Participate in Upcoming Investment Conferences (GlobeNewswire)
Feb-24-22 08:10AM	COCP: Cocrystal Pharma has secured funding to enter three clinical trials and fund planned operations through 2023 (Zacks Small Cap Research)
Jan-27-22 12:22PM	Cocrystal Pharma To Develop Additional Two Antiviral Drug Candidates For COVID-19 (Benzinga)
08:00AM	Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program (GlobeNewswire)
Jan-11-22 07:00AM	SomaLogic Announces Preliminary Revenue for Full Year 2021 Above Guidance Range (GlobeNewswire)
Jan-10-22 04:10PM	SomaLogic Announces Appointment of Adam Taich as Chief Business Officer (GlobeNewswire)
Jan-06-22 08:00AM	Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205 (GlobeNewswire)
Jan-04-22 08:00AM	Cocrystal Pharma to Present at the H.C. Wainwright BioConnect Virtual Conference (GlobeNewswire)
Dec-22-21 08:00AM	Cocrystal Pharmas COVID-19 Oral and Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful In Vitro Potency Against the SARS-CoV-2 Omicron Variant (GlobeNewswire)
Dec-02-21 08:00AM	Cocrystal Pharma to Discuss Progress with COVID-19 Antiviral Programs and Clinical Strategy During Noble Capital Markets Channelchek Virtual Roadshow (GlobeNewswire) -9.15%
Dec-01-21 04:05PM	Cocrystal Pharma Presents Preclinical Data from COVID-19 Antiviral Programs and Outlines Near-Term Clinical Plans at the World Antiviral Congress 2021 (GlobeNewswire) -6.42%
Nov-15-21 12:25PM	Cocrystal Pharma, Inc. (COCP) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Cocrystal Pharma Reports Third Quarter Financial Results and Provides an Update on Development Programs and Milestones (GlobeNewswire)
Nov-08-21 03:00PM	Will Cocrystal Pharma, Inc. (COCP) Report Negative Q3 Earnings? What You Should Know (Zacks)
08:00AM	Cocrystal Pharmas SARS-CoV-2 Main Protease Inhibitors Demonstrate Pan-viral Activity against Human Common Coronaviruses, Noroviruses, Rhinoviruses, and Enteroviruses (GlobeNewswire)
Nov-01-21 08:00AM	Cocrystal Pharma Submits Pre-Investigational New Drug Briefing Package to the FDA for Clinical Development Guidance of CDI-45205 for COVID-19 Treatment (GlobeNewswire) +5.92%
Oct-21-21 08:00AM	Cocrystal Pharma to Present Data from its Oral and Intranasal COVID-19 Therapeutics Programs at the World Antiviral Congress 2021 (GlobeNewswire)
Oct-14-21 08:00AM	Cocrystal Pharma to Present at the Dawson James 2021 Small Cap Growth Conference on October 21, 2021 (GlobeNewswire)
Oct-06-21 08:49AM	Cocrystal Pharma Receives Australian Regulatory Clearance to Initiate Phase 1 Study of CC-42344 for the Treatment of Pandemic and Seasonal Influenza (GlobeNewswire)
Oct-01-21 07:04AM	Here's Why We're Not Too Worried About Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Situation (Simply Wall St.)
Sep-07-21 08:00AM	Cocrystal Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Aug-16-21 09:25AM	Cocrystal Pharma, Inc. (COCP) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
08:00AM	Cocrystal Pharma Reports Second Quarter 2021 Financial Results and Provides Antiviral Program and Milestone Updates (GlobeNewswire)
Jul-29-21 03:04PM	Will Cocrystal Pharma, Inc. (COCP) Report Negative Q2 Earnings? What You Should Know (Zacks) +9.09%
08:00AM	Cocrystal Pharmas SARS-CoV-2 3CL Protease Lead CDI-45205 Demonstrates Broad-Spectrum Activity Against the SARS-CoV-2 Delta and Gamma Variants (GlobeNewswire)
Jun-28-21 08:00AM	Cocrystal Joins Russell Microcap® Index (GlobeNewswire)
Jun-23-21 08:00AM	Cocrystal Pharma Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter (GlobeNewswire)
Jun-15-21 12:03PM	Cocrystal's (COCP) Antiviral CDI-45205 Effective Against COVID-19 (Zacks) -5.84%
Jun-14-21 09:48AM	Cocrystal Pharma's Preclinical Protease Inhibitor Effective Against Original, Two Variant COVID-19 Strains (Benzinga) +9.60%
08:30AM	Cocrystals Lead COVID-19 Antiviral CDI-45205 Shown to be Active Against SARS-CoV-2 and Two Prominent SARS-CoV-2 Variants (GlobeNewswire)
Jun-09-21 02:30PM	Cocrystal Pharmas Participation in the Noble Capital Markets C-Suite Interview Series is Now Available Online (GlobeNewswire)
May-28-21 08:00AM	Cocrystal Pharma Announces the Passing of Chairman, CEO and Co-founder Dr. Gary Wilcox (GlobeNewswire)

Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. It focuses on the preclinical and early clinical stage antiviral compounds for unmet medical needs including influenza, Hepatitis C virus, and norovirus infections. The company was founded in 2008 and is headquartered in Bothell, WA.

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

OPK

Opko Health Inc

BCDA

BioCardia Inc.

FLNT

Fluent Inc

COCP

Cocrystal Pharma Inc

Upgrade your FINVIZ experience